Financial Analysis: Elutia (NASDAQ:ELUT) & Hamilton Thorne (OTCMKTS:HTLZF)

Hamilton Thorne (OTCMKTS:HTLZF) and Elutia (NASDAQ:ELUT) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, institutional ownership, earnings and profitability.

Analyst Recommendations

This is a breakdown of recent ratings for Hamilton Thorne and Elutia, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hamilton Thorne	0	0	0	0	0.00
Elutia	1	0	1	0	2.00

Elutia has a consensus price target of $6.00, suggesting a potential upside of 588.07%. Given Elutia’s stronger consensus rating and higher probable upside, analysts plainly believe Elutia is more favorable than Hamilton Thorne.

Valuation & Earnings

This table compares Hamilton Thorne and Elutia”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hamilton Thorne	N/A	N/A	N/A	N/A	N/A
Elutia	$12.29 million	3.04	$53.38 million	$0.86	1.01

Elutia has higher revenue and earnings than Hamilton Thorne.

Profitability

This table compares Hamilton Thorne and Elutia’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hamilton Thorne	N/A	N/A	N/A
Elutia	312.09%	N/A	-53.97%

Insider & Institutional Ownership

74.0% of Elutia shares are held by institutional investors. 17.8% of Elutia shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Elutia beats Hamilton Thorne on 7 of the 8 factors compared between the two stocks.

About Hamilton Thorne

Hamilton Thorne Ltd. develops, manufactures, and sells precision instruments, laboratory equipment, consumables, software, and services for the assisted reproductive technologies (ART), research, and cell biology markets. The company offers precision laser systems and imaging systems for biology markets. It also provides test laboratory and endotoxin testing services, as well as sperm assays, including Sperm Motility Index and Sperm Penetration; and fresh and cryopreserved mouse embryos supply, and technician training and proficiency testing services. In addition, the company manufactures and distributes medical products for reproductive medicine; manufactures bespoke workstations, incubators, and equipment for IVF laboratories; researches, designs, develops, sells, installs, and services in-vitro diagnostic systems; and manufactures ovum pickup needles, catheters, and other devices. Further, the company offers Cell-Tek Microscope Chamber, a product for controlling temperature, air flow, humidification, and air quality; laminar flow workstations, incubators, and related products; and artificial intelligence enabled CASA software, consumables, and image analysis systems for the ART and laboratory markets, as well as capital equipment and consumables, software, and other services. It sells its products and services under Hamilton Thorne, Gynemed, Planer, Tek-Event, IVFtech, MICROPTIC, Gynétics, and Embryotech brand names through a direct sales force in the United States, Germany, France, Australia, Denmark, Belgium, Spain, and the United Kingdom, as well as through distributors to fertility clinics, hospitals, pharmaceutical companies, biotechnology companies, educational institutions, and other commercial and academic research establishments in approximately 100 countries. Hamilton Thorne Ltd. is headquartered in Beverly, Massachusetts.

About Elutia

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.